Glaucoma Appeal drives research momentum

We thank our generous donors for supporting ground-breaking research that is finding new ways to understand, diagnose and treat glaucoma.


Eye-News emails are sent to
subscribers once a month

Share this article

Our incredible community of supporters have come together through our annual Glaucoma Appeal to raise vital funds for glaucoma research.

The appeal will provide a significant boost to our glaucoma research program, which spans lab-based science through to patient trials.

This support enables us to tackle this complex disease from all angles, including enhancing our understanding of its causes, finding ways to detect it earlier and developing new treatments to save sight.

“Thank you to everyone who contributed to our appeal. Every donation, no matter how small, helps us keep working towards new treatments in glaucoma research,” says Professor Keith Martin, Managing Director of CERA.

Advancing glaucoma research

CERA’s researchers are among the world’s top scientists investigating the causes of glaucoma and how it can be better treated. This includes Dr Flora Hui who is currently trialling an innovative new treatment for glaucoma.

Dr Hui’s previous research has shown the potential of nicotinamide (a form of vitamin B3) to slow the progression of vision loss in glaucoma. The follow-up study she is leading will determine if the supplement could be used in standard clinical care for glaucoma.

This is just one of many research projects at CERA that have the potential for real-life impact on patients – and our supporters play a crucial role in helping us get there.

“All of the researchers at CERA are deeply grateful to the hundreds of people who contribute to make our achievements possible,” says Dr Hui.

Uniting for a glaucoma-free world

This year’s appeal coincided with World Glaucoma Week, under the theme ‘Uniting for a glaucoma-free world’.

Professor Martin believes the success of the Glaucoma Appeal comes down to a shared vision for a world where no one loses their sight from glaucoma.

“We’re proud to help lead the way towards improved understanding of glaucoma and explore potential new therapies, which we hope will be able to protect the vision of those who do not respond to current therapies,” he says.

“We’re incredibly grateful to everyone who is joining us on this journey.”

If you’d like to help future generations be free from glaucoma, there’s still time to support our work.

Subscribe to our Newsletter
Newsletter Subscribe
Receive Appeals